Skip to content
PubMed This is a summary of 73 peer-reviewed journal articles Updated
Nephrology

Membranoproliferative Glomerulonephritis (MPGN): A Patient Guide

At a Glance

MPGN is a pattern of injury in the kidney’s filtering units, not one single disease. Finding whether infection, autoimmune disease, monoclonal proteins, or an overactive complement system is driving the injury helps doctors choose treatment and monitor proteinuria and kidney function over time.

Membranoproliferative Glomerulonephritis, commonly known as MPGN, is a complex diagnosis that describes a specific pattern of injury within the kidneys’ microscopic filtering units, the glomeruli. It is not a single disease, but rather a way the kidneys respond to various forms of stress or immune system dysfunction. Under a microscope, this pattern is characterized by a thickening of the filter walls and an overgrowth of supporting cells, which impairs the kidneys’ ability to filter waste and maintain the body’s fluid balance [1][2].

The most critical step following an MPGN diagnosis is uncovering the “root cause” driving this injury. Modern medicine uses a clinicopathologic approach that categorizes the condition based on biopsy findings and systemic lab tests. Immune-Complex MPGN (IC-MPGN) is often driven by external factors such as chronic infections, autoimmune disorders, or abnormal monoclonal proteins, though sometimes it occurs without a clear external trigger (idiopathic). In contrast, C3 Glomerulopathy (C3G) is typically driven by a malfunction of the complement system, a part of the innate immune system that becomes overactive [3][4]. However, there is overlap between these categories, making a thorough medical evaluation essential [5].

Living with MPGN or C3G requires a long-term commitment to monitoring and specialized care. Because the condition can be progressive—sometimes gradually and sometimes rapidly—your medical team will closely track markers of kidney health, particularly the amount of protein leaking into your urine (proteinuria) and your overall filtration rate (eGFR). These labs serve as an ongoing guide, allowing your doctors to see how the disease is behaving and whether your kidneys are under increasing strain [6][7].

While a diagnosis of an uncommon kidney disease is serious, the landscape of treatment is evolving. Care generally begins with foundational kidney protection, followed by therapies tailored to your specific cause. This may include treating underlying infections, utilizing immunosuppressants, or using new classes of medications called complement inhibitors that can dial down an overactive immune response [8][9]. By focusing on the underlying biology, your care team aims to protect your kidney function and provide a clearer, personalized path forward.

Common questions in this guide

What does an MPGN diagnosis mean?
MPGN describes a pattern of injury in the kidney's glomeruli, the tiny filtering units, rather than one single disease. The pattern includes thickening of filter walls and overgrowth of supporting cells, which can reduce the kidneys' ability to filter waste and balance fluids.
What can cause MPGN or a related C3 glomerulopathy?
Immune-complex MPGN may be linked to chronic infections, autoimmune disorders, or abnormal monoclonal proteins, although no trigger is found in some cases. C3 glomerulopathy is usually associated with an overactive or poorly controlled complement system.
How do doctors find the cause of MPGN?
Doctors combine kidney-biopsy findings with blood, urine, and other systemic tests. This evaluation looks for infection, autoimmune disease, monoclonal proteins, and complement-system problems so treatment can be matched to the underlying driver.
Why are proteinuria and eGFR checked regularly?
Proteinuria measures how much protein is leaking into the urine, while eGFR estimates how well the kidneys filter blood. Tracking both over time helps the care team judge whether the condition is stable or worsening and whether the treatment plan is working.
What treatments may be used for MPGN?
Treatment depends on what is causing the kidney injury. Care may include kidney-protective measures, treating an underlying infection, immunosuppressive medicines, or complement inhibitors when appropriate.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on membranoproliferative glomerulonephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific findings on my biopsy led to the 'MPGN pattern' diagnosis?
  2. 2.Have we definitively identified whether my condition is secondary to another issue or if it is considered primary disease?
  3. 3.What is the primary driver of my kidney injury—is it an infection, an autoimmune issue, a monoclonal protein, or my complement system?
  4. 4.Which targeted treatment or supportive care options are most appropriate for my specific case?
  5. 5.How will we monitor my proteinuria and kidney function to determine if our current plan is working?

References

References (9)
  1. 1

    Membranoproliferative Glomerulonephritis Pattern of Injury.

    Yu SM, Deoliveira M, Chung M, Lafayette R

    Advances in kidney disease and health 2024; (31(3)):216-222 doi:10.1053/j.akdh.2024.03.005.

    PMID: 39004461
  2. 2

    Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.

    Rudnicki M

    BioMed research international 2017; (2017()):2180508 doi:10.1155/2017/2180508.

    PMID: 28573137
  3. 3

    Finding the etiology of membranoproliferative glomerulonephritis.

    Sethi S

    Kidney international 2026; (110(1)):8-15 doi:10.1016/j.kint.2026.02.030.

    PMID: 41895686
  4. 4

    Clinico-Pathogenic Similarities and Differences between Infection-Related Glomerulonephritis and C3 Glomerulopathy.

    Wada Y, Kamata M, Miyasaka R, et al.

    International journal of molecular sciences 2023; (24(9)) doi:10.3390/ijms24098432.

    PMID: 37176142
  5. 5

    [Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury].

    Rudnicki M, Windpessl M, Eller K, et al.

    Wiener klinische Wochenschrift 2023; (135(Suppl 5)):688-695 doi:10.1007/s00508-023-02264-7.

    PMID: 37728653
  6. 6

    Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative GN.

    Nanchen G, Marasà M, Breno M, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2026; (21(4)):626-640 doi:10.2215/CJN.0000000953.

    PMID: 41433110
  7. 7

    Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.

    Caravaca-Fontán F, Toledo-Rojas R, Huerta A, et al.

    Kidney international reports 2025; (10(4)):1223-1236 doi:10.1016/j.ekir.2025.01.024.

    PMID: 40303231
  8. 8

    Primary membranoproliferative glomerulonephritis: natural history, pathogenesis, and treatment.

    Filippone EJ, Farber JL

    Frontiers in nephrology 2026; (6()):1747678 doi:10.3389/fneph.2026.1747678.

    PMID: 41767602
  9. 9

    Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

    Fakhouri F, Bomback AS, Ariceta G, et al.

    The New England journal of medicine 2025; (393(22)):2210-2220 doi:10.1056/NEJMoa2501510.

    PMID: 41337715

This MPGN page is for informational purposes only and does not constitute medical advice. A nephrologist and your care team should interpret your biopsy and test results and recommend treatment for your specific situation.